Literature DB >> 19419295

Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men.

Sherri-Ann M Burnett-Bowie1, Maria P Henao, Melissa E Dere, Hang Lee, Benjamin Z Leder.   

Abstract

Fibroblast growth factor 23 (FGF23) promotes phosphaturia and suppresses 1,25-dihydroxyvitamin D [1,25(OH)(2)D] production. PTH also promotes phosphaturia, but, in contrast, stimulates 1,25(OH)(2)D production. The relationship between FGF23 and PTH is unclear, and the acute effect of pharmacologically dosed PTH on FGF23 secretion is unknown. Twenty healthy men were infused with human PTH(1-34) [hPTH(1-34)] at 44 ng/kg/h for 24 h. Compared with baseline, FGF23, 1,25(OH)(2)D, ionized calcium (iCa), and serum N-telopeptide (NTX) increased significantly over the 18-h hPTH(1-34) infusion (p < 0.0001), whereas serum phosphate (PO(4)) transiently increased and then returned to baseline. FGF23 increased from 35 +/- 10 pg/ml at baseline to 53 +/- 20 pg/ml at 18 h (p = 0.0002); 1,25(OH)(2)D increased from 36 +/- 16 pg/ml at baseline to 80 +/- 33 pg/ml at 18 h (p < 0.0001); iCa increased from 1.23 +/- 0.03 mM at baseline to 1.46 +/- 0.05 mM at hour 18 (p < 0.0001); and NTX increased from 17 +/- 4 nM BCE at baseline to 28 +/- 8 nM BCE at peak (p < 0.0001). PO(4) was 3.3 +/- 0.6 mg/dl at baseline, transiently rose to 3.7 +/- 0.4 mg/dl at hour 6 (p = 0.016), and then returned to 3.4 +/- 0.5 mg/dl at hour 12 (p = 0.651). hPTH(1-34) infusion increases endogenous 1,25(OH)(2)D and FGF23 within 18 h in healthy men. Whereas it is possible that the rise in PO(4) contributed to the observed increase in FGF23, the increase in 1,25(OH)(2)D was more substantial and longer sustained than the change in serum phosphate. Given prior data that suggest that neither PTH nor calcium stimulate FGF23 secretion, these data support the assertion that 1,25(OH)(2)D is a potent physiologic stimulator of FGF23 secretion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19419295      PMCID: PMC2743281          DOI: 10.1359/jbmr.090406

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  28 in total

1.  Evidence for a bone-kidney axis regulating phosphate homeostasis.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

2.  FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.

Authors:  Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  J Bone Miner Res       Date:  2003-12-29       Impact factor: 6.741

3.  Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men.

Authors:  Sherri-Ann M Burnett-Bowie; Natalia Mendoza; Benjamin Z Leder
Journal:  Bone       Date:  2006-12-08       Impact factor: 4.398

4.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

Authors:  Yuji Yamazaki; Ryo Okazaki; Minako Shibata; Yukihiro Hasegawa; Kohei Satoh; Toshihiro Tajima; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Takeyoshi Yamashita; Seiji Fukumoto
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

5.  Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Susan M Sereika; Bruce W Hollis; Adolfo Garcia-Ocaña; Andrew F Stewart
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

6.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

7.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.

Authors:  T Shimada; S Mizutani; T Muto; T Yoneya; R Hino; S Takeda; Y Takeuchi; T Fujita; S Fukumoto; T Yamashita
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

8.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Authors:  Kenneth B Jonsson; Richard Zahradnik; Tobias Larsson; Kenneth E White; Toshitsugu Sugimoto; Yasuo Imanishi; Takehisa Yamamoto; Geeta Hampson; Hiroyuki Koshiyama; Osten Ljunggren; Koichi Oba; In Myung Yang; Akimitsu Miyauchi; Michael J Econs; Jeffrey Lavigne; Harald Jüppner
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

9.  Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism.

Authors:  Hiroyuki Yamashita; Takeyoshi Yamashita; Masashi Miyamoto; Takashi Shigematsu; Junichiro James Kazama; Takashi Shimada; Yuji Yamazaki; Seiji Fukumoto; Masafumi Fukagaw; Shiro Noguchi
Journal:  Eur J Endocrinol       Date:  2004-07       Impact factor: 6.664

10.  Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

Authors:  Tobias Larsson; Ulf Nisbeth; Osten Ljunggren; Harald Jüppner; Kenneth B Jonsson
Journal:  Kidney Int       Date:  2003-12       Impact factor: 10.612

View more
  40 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  FGF23 and PTH--double agents at the heart of CKD.

Authors:  Justin Silver; Mariano Rodriguez; Eduardo Slatopolsky
Journal:  Nephrol Dial Transplant       Date:  2012-03-23       Impact factor: 5.992

3.  Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.

Authors:  Stuart M Sprague; James B Wetmore; Konstantin Gurevich; Gerald Da Roza; John Buerkert; Maureen Reiner; William Goodman; Kerry Cooper
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-14       Impact factor: 8.237

Review 4.  Role of αKlotho and FGF23 in regulation of type II Na-dependent phosphate co-transporters.

Authors:  Ming Chang Hu; Mingjun Shi; Orson W Moe
Journal:  Pflugers Arch       Date:  2018-12-01       Impact factor: 3.657

5.  A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.

Authors:  Shoji Ichikawa; Anthony M Austin; Amie K Gray; Michael J Econs
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

6.  Renal phosphate wasting in the absence of adenylyl cyclase 6.

Authors:  Robert A Fenton; Fiona Murray; Jessica A Dominguez Rieg; Tong Tang; Moshe Levi; Timo Rieg
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

7.  Lack of FGF23 response to acute changes in serum calcium and PTH in humans.

Authors:  Katherine Wesseling-Perry; Hejing Wang; Robert Elashoff; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2014-07-25       Impact factor: 5.958

Review 8.  Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

9.  1alpha,25-dihydroxyvitamin D3 acts predominately in mature osteoblasts under conditions of high extracellular phosphate to increase fibroblast growth factor 23 production in vitro.

Authors:  Ryoko Yamamoto; Tomoko Minamizaki; Yuji Yoshiko; Hirotaka Yoshioka; Kazuo Tanne; Jane E Aubin; Norihiko Maeda
Journal:  J Endocrinol       Date:  2010-06-08       Impact factor: 4.286

Review 10.  The use of fibroblast growth factor 23 testing in patients with kidney disease.

Authors:  Edward R Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.